>

Onno Stolpe - Galapagos CEO

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:4em;padding-top: 25px;;'>GA</div>
GLPG -- USA Stock  

Earnings Report: April 24, 2020  

  CEO
Mr. Onno van de Stolpe has served as Chief Executive Officer, Executive Director, Member of the Executive Committee of Galapagos NV since June 1999. He founded Galapagos in 1999 while he was Managing Director Genomics at Introgene . Prior to joining Introgene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the United States. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager Business Development at MOGEN in Leiden. He currently also serves as a member of the supervisory board of the Stichting Institute for Human Organ and Disease Model Technologies and has previously served as a member of the board of directors of DCPrime B.V
Age: 57  CEO Since 1999      
32 1 534 29 00  http://www.glpg.com
Onno van de Stolpe received a MS degree from the Agricultural University in Wageningen.

Management Efficiency

The company has return on total asset (ROA) of (0.02) % which means that it has lost $0.02 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.03) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 225.92 K in liabilities with Debt to Equity (D/E) ratio of 0.9 which is about average as compared to similar companies. Galapagos NV has Current Ratio of 8.77 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 8 records

CEO Since

Ryan WattsDenali Therapeutics
2016
Barry SimonNantKwest
2017
Jeffrey BachaDelMar Pharmaceuticals
2018
Eddie GrayDynavax Technologies Corporatio
2013
Douglas FambroughDicerna Pharmaceuticals
2010
Rick PaulsDiaMedica Therapeutics
2014
Geoffrey RotsteinEquillium
2006
Katrine BosleyEditas Medicine
2019

Company Summary

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. The company was founded in 1999 and is headquartered in Mechelen, Belgium. Galapagos operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 918 people.Galapagos NV (GLPG) is traded on BATS Exchange in USA. It is located in Generaal De Wittelaan L11 A3 and employs 918 people. Galapagos is listed under Pharmaceutical Products category by Fama And French industry classification.

Galapagos NV Leadership Team

Rajesh Parekh, Non-Executive Chairman of the BoardView
Andre Hoekema, Sr. VP of Corporate Devel.View
Katrine Bosley, Independent Non-Executive DirectorView
Walid AbiSaab, Member of the Executive Committee, Chief Medical OfficerView
Howard Rowe, Non-Executive Independent DirectorView
Harrold Barlingen, Non-Executive DirectorView
Elizabeth Goodwin, VP Corporate Communications & Investor RelationsView
Mary Kerr, Non-Executive Independent DirectorView
Piet Wigerinck, Chief Scientific OfficerView
Christine Mummery, Non-Executive Independent DirectorView
Bart Filius, CFOView
Onno Stolpe, Co-Founder, CEO, Managing Director and Executive DirectorView
Werner Cautreels, Non-Executive Independent DirectorView

Stock Performance Indicators

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.